Related Experiment Video

Updated: Jun 10, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2

Stefania Mitola1, Cosetta Ravelli, Emanuela Moroni

  • 1Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Viale Europa 11, Brescia, Italy.

Blood
|July 28, 2010
PubMed

Insights

Gremlin, a bone morphogenic protein antagonist, acts as a novel proangiogenic vascular endothelial growth factor receptor-2 (VEGFR2) agonist. This finding has implications for understanding tumor neovascularization and related diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Developmental Biology

Background:

  • Gremlin is a bone morphogenic protein antagonist involved in embryonic development and pathological conditions like cancer.
  • Gremlin is a proangiogenic protein within the cystine-knot superfamily, related to TGF-β and VEGFs.

Purpose of the Study:

  • To investigate the interaction between gremlin and VEGF receptor-2 (VEGFR2).
  • To determine if gremlin can activate VEGFR2 and induce angiogenic responses.
  • To explore the implications of gremlin's proangiogenic activity in vascular development and disease.

Main Methods:

  • Binding assays to assess gremlin's interaction with VEGFR2.
  • Endothelial cell cultures to study VEGFR2 activation by gremlin.
  • In vitro and in vivo models to evaluate gremlin-induced angiogenic responses.

Main Results:

  • Gremlin binds to VEGFR2 independently of bone morphogenic proteins.
  • Gremlin activates VEGFR2 in endothelial cells, similar to VEGF-A.
  • Gremlin elicits VEGFR2-dependent angiogenic responses both in vitro and in vivo.

Conclusions:

  • Gremlin is a novel proangiogenic VEGFR2 agonist, distinct from VEGF family ligands.
  • Gremlin's activity has significant implications for vascular development, angiogenesis-dependent diseases, and tumor neovascularization.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...